Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

161.46 +0.95 (+0.59%)
Official Closing Price Updated: 7:00 PM EDT, Oct 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,253,465
Open 162.18
Bid (Size) 161.25 (1)
Ask (Size) 161.46 (10)
Prev. Close 160.51
Today's Range 161.20 - 162.66
52wk Range 143.13 - 168.85
Shares Outstanding 2,628,679,824
Dividend Yield 2.95%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Johnson & Johnson Dividend Stock Analysis - Saturday, Oct. 12
Johnson & Johnson is a leader in the pharmaceutical, medical device, and consumer products industries. Here are some highlights from a quantitative analysis of the company's stock. 
Via Talk Markets
Stocks Extend Weekly Win Streaks To 5
Wall Street enjoyed healthy gains to close out both the day and week. 
Via Talk Markets

Performance

YTD
+0.93%
+0.93%
1 Month
-2.04%
-2.04%
3 Month
+7.73%
+7.73%
6 Month
+9.45%
+9.45%
1 Year
+3.28%
+3.28%

More News

Read More
Market Whales and Their Recent Bets on JNJ Options
Via Benzinga
World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice
Via Benzinga
Johnson & Johnson to Participate in the Stifel 2024 Healthcare Conference
From Johnson & Johnson
Via Business Wire
What Analysts Are Saying About Johnson & Johnson Stock
Via Benzinga
3 Mega-Cap Stocks For Long-Term Dividend Growth
Via Talk Markets
Insights Into Johnson & Johnson's Performance Versus Peers In Pharmaceuticals Sector
Via Benzinga
Johnson & Johnson Completes Acquisition of V-Wave
From Johnson & Johnson
Via Business Wire
1 Vanguard Index Fund Could Turn $500 Per Month Into a $968,400 Portfolio That Pays $16,000 in Annual Dividend Income
Via The Motley Fool
Should Investors Consider High Yield Dividend Stocks?
Via Talk Markets
What To Expect When Johnson & Johnson Reports Q3 Earnings Next Week?
Via Benzinga
Exposures Product Safety
Top 3 Risk-Averse Stocks to Add Stability to Your Portfolio
Via MarketBeat
Johnson & Johnson's Options: A Look at What the Big Money is Thinking
Via Benzinga
3 Undervalued Dividend Stocks Primed for Growth in 2025
Via MarketBeat
Johnson & Johnson to Participate in the Guggenheim Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization
Via Benzinga
2 Smart Income Stocks to Buy Right Now
Via The Motley Fool
3 Industries Set To Explode When Interest Rates Drop
Via Talk Markets
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
Via Investor Brand Network
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
Via FinancialNewsMedia
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Johnson & Johnson's Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer's Drug
Via Benzinga
Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients
Via Benzinga
15 Best Dividend Stocks for Lifelong Passive Income
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.